Skip to main content
Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.305
+0.005 (0.22%)
Mar 9, 2026, 3:04 PM EDT - Market open

Spero Therapeutics Revenue

Spero Therapeutics had revenue of $5.44M in the quarter ending September 30, 2025, a decrease of -59.60%. This brings the company's revenue in the last twelve months to $40.55M, down -61.91% year-over-year. In the year 2024, Spero Therapeutics had annual revenue of $47.98M, down -53.77%.

Revenue (ttm)
$40.55M
Revenue Growth
-61.91%
P/S Ratio
3.08
Revenue / Employee
$1,267,156
Employees
32
Market Cap
129.86M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202447.98M-55.80M-53.77%
Dec 31, 2023103.78M50.27M93.95%
Dec 31, 202253.51M35.25M193.10%
Dec 31, 202118.26M8.93M95.67%
Dec 31, 20209.33M-8.82M-48.59%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Sangamo Therapeutics 32.88M
Oramed Pharmaceuticals 2.00M
Connect Biopharma Holdings 762.00K
Cardiff Oncology 593.00K
Inovio Pharmaceuticals 182.34K
Adagene 103.20K
Genelux 8.00K
Revenue Rankings

SPRO News

More News